From the beginning of its membership in NIDA's Clinical Trials Network (CTN) in 2000, the Ohio Valley Node (OVN) has been an effective, enthusiastic, and energetic node that has excelled in providing scientific and administrative leadership, in collaborating with other nodes and with NIDA and contract staff, and in disseminating information about evidence-based practices and the results of CTN studies. The OVN's Community Treatment Programs (CTPs) and its Regional Research and Training Center (RRTC) have worked together to create a node in which the CTN's goal of bilateral communication/collaboration between researchers and treatment providers has been fully realized. The success in integrating all members of this geographically dispersed node into a unified whole, together with the strong commitment of the Node PI, CTP PIs, and RRTC staff to full participation in the CTN, have enabled the OVN to be extremely productive throughout its membership in the CYN. The OVN has an experienced staff, including several RRTC and CTP PIs who have been with the OVN since its formation. The OVN continues to collaborate with a growing number of CTPs which have a variety of patient characteristics and extend over a broad geographical range now encompassing the entire Midwest (12 states) and the Upper-South states of Kentucky, Tennessee, and West Virginia. The 23 OVN CTPs, which together receive more than 100,000 patient visits a year, will contribute significantly to the number and variety of potential participants for CTN studies. The OVN administrative and management plans for the next five years capitalize on the strengths of the OVN: experience, teamwork, and varied areas of expertise (including HIV/AIDS, emergency medicine, integration of addiction treatment into primary care, and telemedicine), so the OVN can continue to contribute scientific leadership and excellence in developing/conducting CTN protocols. The OVN has detailed a research agenda designed to improve opioid dependence treatment by optimizing medication-assisted treatment and expanding office-based opioid treatment. Already cooperating actively with the four Addiction Technology and Transfer Centers (ATTCs) associated with the states covered by the OVN, the Node plans to strengthen relationships with other networks (e.g., Cincinnati Center for Clinical &Translational Science &Training).

Public Health Relevance

To further the goal of expanding substance abuse care and research into non-traditional settings, Ohio Valley Node Community Treatment Programs now include an HIV/AIDS clinic, two primary care centers, and two hospital emergency departments. The Ohio Valley Node's research agenda is designed to improve opioid dependence treatment by optimizing medication-assisted treatment and expanding office-based opioid treatment, including a new mechanism for dosing buprenorphine which would reduce diversion.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10DA013732-12S3
Application #
8460234
Study Section
Special Emphasis Panel (ZDA1-KXH-C (04))
Program Officer
Dobbins, Ronald
Project Start
2000-09-30
Project End
2015-08-31
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
12
Fiscal Year
2012
Total Cost
$633,443
Indirect Cost
$14,250
Name
University of Cincinnati
Department
Psychiatry
Type
Schools of Medicine
DUNS #
041064767
City
Cincinnati
State
OH
Country
United States
Zip Code
45221
Winhusen, Theresa; Feaster, Daniel J; Duan, Rui et al. (2017) Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection. AIDS Behav :
Trivedi, Madhukar H; Greer, Tracy L; Rethorst, Chad D et al. (2017) Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder: Results From the CTN-0037 STimulant Reduction Intervention Using Dosed Exercise (STRIDE) Study. J Clin Psychiatry 78:1075-1082
Lévesque, Annie; Campbell, Aimee N C; Pavlicova, Martina et al. (2017) Coping strategies as a mediator of internet-delivered psychosocial treatment: Secondary analysis from a NIDA CTN multisite effectiveness trial. Addict Behav 65:74-80
Korthuis, Philip T; Lum, Paula J; Vergara-Rodriguez, Pamela et al. (2017) Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. Addiction 112:1036-1044
Pan, Yue; Liu, Hongmei; Metsch, Lisa R et al. (2017) Factors Associated with HIV Testing Among Participants from Substance Use Disorder Treatment Programs in the US: A Machine Learning Approach. AIDS Behav 21:534-546
Worley, Matthew J; Heinzerling, Keith G; Shoptaw, Steven et al. (2017) Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction. Addiction 112:1202-1209
Babalonis, Shanna; Haney, Margaret; Malcolm, Robert J et al. (2017) Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend 172:9-13
Lee, J D; Tofighi, B; McDonald, R et al. (2017) Acceptability and effectiveness of a web-based psychosocial intervention among criminal justice involved adults. Health Justice 5:3
Blanco, Carlos; Campbell, Aimee N; Wall, Melanie M et al. (2017) Toward National Estimates of Effectiveness of Treatment for Substance Use. J Clin Psychiatry 78:e64-e70
Winhusen, Theresa; Lewis, Daniel (2017) Cigarette smoking in pregnant substance users: Association with substance use and desire to quit. J Addict Dis 36:88-91

Showing the most recent 10 out of 130 publications